A population-based cohort study carried out over 2 years aimed to assess the risk of severe urinary tract infections in type 2 diabetic patients initiating SGLT2 inhibitors compared to those initiating DPP inhibitors and GLP1-RA; the results showed that the risk of severe urinary tract infections among patients initiating SGLT2 inhibitors was similar to that among patients initiating DPP inhibitors (HR 0.98) and GLP1-RA (HR 0.72) [32]. The gene discussed is SLC5A2; the disease is urinary tract infection.